HC Wainwright & Co. Reiterates Buy on Barinthus Biotherapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen reiterates a Buy rating on Barinthus Biotherapeutics (NASDAQ:BRNS) and maintains a $5 price target.
August 12, 2024 | 11:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Yi Chen reiterates a Buy rating on Barinthus Biotherapeutics (NASDAQ:BRNS) and maintains a $5 price target.
The reiteration of a Buy rating and the maintenance of a $5 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100